SES-S.A.
SES S.A. (Euronext Paris:SESG) (LuxX:SESG) announced today that MX1, a wholly-owned subsidiary of SES and a global media service provider, and ASTRA, the largest European Direct-to-Home (DTH) satellite system, have extended their contracts with Discovery Networks Germany for capacity, content management and playout.
This Smart News Release features multimedia. View the full release here: http://www.businesswire.com/news/home/20161222005208/en/
The contract covers the broadcasting of the Discovery channels DMAX, TLC, Eurosport 1 and DMAX Austria in SD, and DMAX, TLC and Eurosport 1 in HD via the ASTRA satellites at 19.2 degrees East. The agreement also allows Discovery Networks Germany to use the innovative media service platform “MX1 360” for content management and playout. The “MX1 360” platform is fully integrated with the broadcaster’s systems and facilitates the management of pre-broadcast features such as planning commercial breaks from a single interface.
“We are very happy that Discovery Networks Germany relies on us as their preferred partner for services and distribution, and has chosen to extend their contracts for SD and HD on a longer-term basis,” commented Christoph Mühleib, Vice President Sales and Marketing SES and responsible for MX1 and ASTRA in Germany, Austria and Switzerland. “Discovery can count on the parallel broadcasting of their channels in SD and HD at least until 2021, and thus, optimize its technical reach in the German market.”
Omar Asmar, Director Media Operations at Discovery Networks Deutschland, said “on the one hand, we rely on optimized workflow, and on the other, we want to reach as large an audience as possible with our content. Thus, MX1 and ASTRA are, very clearly, our ideal partners. The service platform MX1 360 is seamlessly integrated into our processes and systems, so that we can have complete control over all stages of broadcasting preparation including monitoring content to enhance the protection of youth. Furthermore, the broadcasting via the ASTRA satellite at 19.2 degrees East in SD and HD provides maximum reach for our channels. We are looking forward to a continuing successful collaboration in the coming years.”
Follow us on:
Twitter: https://twitter.com/SES_Satellites
Facebook: https://www.facebook.com/SES.YourSatelliteCompany
YouTube: http://www.youtube.com/SESVideoChannel
Blog: https://www.ses.com/news/blogs
SES White papers are available under https://www.ses.com/news/whitepapers
About SES
SES is the world-leading satellite operator and the first to deliver a differentiated and scalable GEO-MEO offering worldwide, with more than 50 satellites in Geostationary Earth Orbit (GEO) and 12 in Medium Earth Orbit (MEO). SES focuses on value-added, end-to-end solutions in four key market verticals (Video, Enterprise, Mobility and Government). It provides satellite communications services to broadcasters, content and internet service providers, mobile and fixed network operators, governments and institutions, and businesses worldwide. SES’s portfolio includes the ASTRA satellite system, which has the largest Direct-to-Home (DTH) television reach in Europe, and O3b Networks, a global managed data communications service provider. Another SES subsidiary, MX1, is a leading media service provider and offers a full suite of innovative digital video and media services. Further information available at: www.ses.com
About MX1
MX1, a wholly-owned subsidiary of SES (Euronext Paris:SESG) (LuxX:SESG), is a global leading media services provider. The world’s first media globalizer works with leading media businesses to transform content into the ultimate viewer experience for a global audience. With more entertainment, more innovation and more impact, MX1 offers a full range of content management, delivery and value-added digital media services. Every day, MX1 distributes more than 2,500 TV channels, manages the playout of over 500 channels, delivers syndicated content to more than 120 leading subscription VOD platforms, delivers over 8,000 hours of online video streaming and delivers more than 500 hours of premium sports and live events. The new company has 16 offices worldwide and operates six global state-of-the-art media centers, enabling customers to reach billions of people around the world. To find out more, visit www.mx1.com and follow LinkedIn , Twitter , Facebook und YouTube
View source version on businesswire.com: http://www.businesswire.com/news/home/20161222005208/en/
Contact:
SES S.A.
Markus Payer
Corporate Communications
Tel. +352
710 725 500
Markus.Payer@ses.com
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
ImmunAbs Announces FDA Phase 2 IND Approval of IM-101, a Novel Complement C5 Inhibitor, for Treatment of Myasthenia Gravis2.6.2025 13:00:00 CEST | Press release
ImmunAbs Inc., a clinical-stage biotech specializing in developing antibody therapeutics, today announced that the U.S. Food and Drug Administration has cleared its Investigational New Drug (IND) application to initiate a Phase 2 clinical trial evaluating the safety and efficacy of IM-101, a novel complement C5 inhibitor, for the treatment of Myasthenia Gravis. The forthcoming multicenter, randomized, double-blind, placebo-controlled study will enroll up to 90 patients to evaluate the effectiveness and safety of monthly IM-101 dosing in relieving complement-induced symptoms in MG. “This IND approval is pivotal for us as it brings us one step closer to delivering a transformative therapy for patients with autoimmune disorders”, said Dr. Dongjo Kim, the CEO of ImmunAbs, “we believe IM-101 has the potential to deliver deeper therapeutic responses and more durable remissions in patients who have failed to achieve sustained remission with current approved treatment.” About Myasthenia Gravis
Lenovo and Bellevue University Team Up to Offer Supply Chain and Logistics Education to Deliver “Smarter Technology for All”2.6.2025 13:00:00 CEST | Press release
Learners will have access to Lenovo’s globally recognized supply chain expertise through real-world case studies and subject matter experts. Lenovo, the global technology powerhouse, recognized in the top 10 in the Gartner Supply Chain Top 25, and Bellevue University, one of the nation’s top online universities, are teaming up to develop the next generation of supply chain professionals. “We believe that bringing real-world Global Supply Chain experience and learning directly into an education curriculum is precisely the optimal way to upskill the workforce of the future,” said Ben Massie, Vice President, Global Supply Chain, Lenovo. “Teaming up with Bellevue allows us to attract the right talent using the right technology and deliver on our mission to make ‘smarter technology for all’ a reality.” As a preferred higher education institution tapped to team up with Lenovo to offer supply chain short-term learning, Bellevue will leverage the breadth and depth of Lenovo’s supply chain expe
Lifezone Metals Files Initial Assessment for the Kabanga Nickel Project in Tanzania2.6.2025 12:30:00 CEST | Press release
Vertically Integrated Plan includes Hydrometallurgical Refinery at Kahama $2.37 Billion After-Tax NPV (8%) and 22.9% After-Tax IRR at $8.49 per Pound Nickel Price Initial Assessment Proposes a 22-Year Mine Plan at Average 2.39% Nickel Equivalent Grade Webcast with Technical Leadership Team at 10 AM ET on Tuesday, June 3, 2025 Lifezone Metals Limited’s (NYSE: LZM) Chief Executive Officer, Chris Showalter, and Chief Operating Officer, Gerick Mouton, announce today the results from the Initial Assessment for its flagship Kabanga Nickel Project in northwest Tanzania. The Initial Assessment evaluates a vertically integrated mining, processing and refining operation, commencing with a high-grade nickel sulfide underground mine and concentrator at the Kabanga site, followed five years later by a hydrometallurgical refinery at Kahama. The study covers the Main, MNB, Kima, North, and Tembo zones and is based on the December 2024 Mineral Resource Update (refer to Lifezone’s December 5, 2024 news
Corpay Cross-Border Named an Official Partner of Real Madrid C.F.2.6.2025 12:00:00 CEST | Press release
Providing access to currency risk management and cross-border payments solutions Corpay, Inc.*, (NYSE: CPAY) a global leader in corporate payments, is pleased to announce that Corpay’s Cross-Border business has entered into an agreement with Real Madrid C.F. to become an Official Partner. Through this partnership, Real Madrid will be able to gain access to and utilise Corpay Cross Border’s innovative solutions to help mitigate foreign exchange exposure from their day-to-day business needs. "The Corpay Cross-Border team is elated to be named an Official Partner of Real Madrid, one of the world’s most widely recognized and followed sports franchises," said Brad Loder, Chief Marketing Officer, Corpay Cross-Border Solutions. “With our strong focus on growing the Corpay brand, as well as our currency risk management business, we are excited to partner with one of the most successful football clubs in the world.” About Corpay Corpay, Inc. (NYSE: CPAY) is a global S&P500 corporate payments co
BeOne Medicines Unveils Promising Clinical Data for Two Novel Breast Cancer Therapies at ASCO 20252.6.2025 12:00:00 CEST | Press release
Preliminary results highlight anti-tumor activity and favorable safety profiles of both B7-H4-targeting ADC and CDK2 inhibitorData underscore strength of emerging breast cancer pipeline as part of BeOne’s global transformation with next wave of innovation BeOne Medicines Ltd. (NASDAQ: ONC; HKEX: 06160; SSE: 688235), a global oncology company, announced new clinical data from its emerging breast cancer pipeline at the American Society of Clinical Oncology (ASCO) Annual Meeting in Chicago. Poster presentations feature preliminary results of the dose escalation studies of two investigational molecules: BG-C9074, a novel B7-H4-targeting antibody-drug conjugate (ADC) in patients with advanced solid tumors, including breast cancer, and BG-68501, a cyclin-dependent kinase-2 inhibitor (CDK2i), in HR+/HER2- breast cancer patients with prior CDK4/6i exposure. “Presenting the first clinical data for two novel breast cancer candidates at ASCO 2025 marks a pivotal moment for BeOne,” said Mark Lanas
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom